Vailan Pharmaceutical-B (02561) has risen over 5%, as of the time of this writing, it increased by 5.39%, priced at 46.9 Hong Kong dollars, with a transaction amount of 2.1721 million Hong Kong dollars.
According to the Zhituo Finance APP, Vailan Pharmaceutical-B (02561) has risen over 5%, as of the time of this writing, it increased by 5.39%, priced at 46.9 Hong Kong dollars, with a transaction amount of 2.1721 million Hong Kong dollars.
In the news, on May 12, Vailan Pharmaceutical announced that its investigational drug Navepegritide (TransCon CNP) for the treatment of achondroplasia (ACH) has successfully completed all phase II clinical trials in China (including a 52-week double-blind treatment period and a 52-week open-label extension phase), and recently registered the clinical trial results on the National Medical Products Administration's "Drug Clinical Trials Registration and Information Publicity Platform." It is reported that the Navepegritide phase II clinical trial in China targeted Chinese children aged 2 to 10 with ACH, using a subcutaneous administration method once a week, aiming to continuously provide active CNP at a safe treatment dose.
In addition, Vailan Pharmaceutical recently had in-depth discussions with investors regarding the company's fundamentals and the development status of its core product pipeline, mentioning that Navepegritide is a potential first-in-class disease-modifying therapy for children with achondroplasia in relevant regions. Currently, there are no similar products approved domestically, and no other companies are conducting relevant research and development. The company plans to design the drug's indications to cover the entire growth and development stage from diagnosis in children to the age of 15. Given the long treatment cycle of over a decade and the clear market exclusivity, this product is expected to achieve annual sales of several hundred million yuan in the future.
